George Eby joins Adeona's SAB
This article was originally published in Scrip
Adeona Pharmaceuticals has appointed George Eby to its scientific advisory board. Though the company focuses on developing treatments for CNS disorders, Mr Eby will provide expertise for its common cold programme, as he has conducted multiple clinical studies of zinc lozenges for the common cold over 30 years as a researcher, and is the executive director of the George Eby Research Institute.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.